On Thursday, Baird upgraded shares of McKesson Corporation (NYSE:MCK) stock from Neutral to Outperform, significantly increasing the price target to $688 from the previous $531. The firm's decision reflects McKesson's strong performance, particularly in the U.S. Pharmaceutical (TADAWUL:2070) Distribution and Prescription Technology Solutions sectors.
The company, which derives approximately 90% of its revenue from U.S. Pharmaceutical Distribution, has seen robust demand for branded and specialty products. This includes an expansion in oncology and biopharma services offerings. Furthermore, the sector is experiencing generally stable to favorable economics for generics, with a substantial wave of new generics and biosimilars expected to be introduced by the end of the decade.
McKesson's recent contract win with OptumRx is set to boost growth in the U.S. Pharmaceutical segment starting in the second quarter of fiscal year 2025. This win is anticipated to positively influence the company's financial performance in fiscal years 2025 and 2026.
The firm also noted that McKesson's Prescription Technology Solutions is benefiting from strong trends in the U.S. pharmaceutical market. There is a growing demand for solutions that improve access to medications, ensure adherence to treatment regimens, and enhance affordability, particularly in the area of prior authorizations.
On the international front, McKesson has largely completed divestitures, including the recent announcement of the sale of its Canadian retail pharmacy and wellness assets. While the wind-down of COVID-related operations in the Medical-Surgical segment has concluded, there has been some near-term performance impact due to weakness in the Primary Care market, which has necessitated restructuring efforts.
In summary, Baird's upgrade of McKesson's stock to Outperform is based on the company's solid sector fundamentals, strategic operations simplification, and recent business developments that are expected to contribute to growth in the coming years.
In other recent news, McKesson Corporation has reported significant developments in its financial performance and strategic initiatives. The company posted strong first-quarter revenues for fiscal 2025 of $79.3 billion, marking a 6% increase from the previous year.
Adjusted earnings per diluted share rose by 8% to $7.88, leading to an updated full-year guidance. In addition, McKesson announced a 15% increase in its quarterly dividend and approved an additional $4 billion for share repurchases.
McKesson has also made notable acquisitions, including Florida Cancer Specialists and a controlling interest in Core Ventures, valued at $2.49 billion. These strategic moves are expected to consolidate Florida Cancer Specialists' procurement operations, adding an estimated $3.6 billion in oncology spending to McKesson's platform.
On the analyst front, Deutsche Bank (ETR:DBKGn) cut its price target for McKesson, while Baird downgraded the stock from "Outperform" to "Neutral." However, firms such as Jefferies, TD Cowen, and BofA Securities maintain a Hold, Buy, and Buy rating respectively, expressing confidence in McKesson's long-term prospects.
Barclays (LON:BARC) has maintained its Equalweight rating for McKesson, acknowledging the company's sequential improvement in organic sales and gross margins. These are the recent developments shaping McKesson's financial and strategic landscape.
InvestingPro Insights
McKesson's recent upgrade by Baird aligns with several key metrics and insights from InvestingPro. The company's market capitalization stands at an impressive $71.23 billion, reflecting its significant presence in the healthcare sector. McKesson's revenue growth of 10.46% over the last twelve months supports Baird's positive outlook on the company's performance in U.S. Pharmaceutical Distribution and Prescription Technology Solutions.
InvestingPro Tips highlight that McKesson has maintained dividend payments for 31 consecutive years and has raised its dividend for 17 consecutive years. This consistent dividend history underscores the company's financial stability and commitment to shareholder returns, which may be attractive to investors considering Baird's upgraded price target.
Additionally, McKesson's strong return over the last month (13.57%) and year-to-date (19.07%) aligns with Baird's optimistic view on the stock's potential. The company's ability to generate sufficient cash flows to cover interest payments, as noted in another InvestingPro Tip, further supports its financial health and ability to invest in growth opportunities like the recent OptumRx contract win.
For investors seeking more comprehensive analysis, InvestingPro offers 13 additional tips that could provide deeper insights into McKesson's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.